Cogent Biosciences, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cogent Biosciences reported Q2 2026 net loss of $96.4M (vs. $73.5M YoY); cash position $792.3M plus $73.6M from ATM offering = $865.9M pro forma, sufficient into late 2028. Three bezuclastinib NDAs submitted: GIST (PDUFA Nov 30, 2026), NonAdvSM (PDUFA Dec 30, 2026), and AdvSM (submitted June 30). PEAK trial showed 50% reduction in disease progression risk vs. sunitinib (HR 0.50); APEX trial showed 65% ORR in Advanced SM. Company hired 59 new employees with inducement grants of 226,700 stock options and 189,700 RSUs.
Why this rating
Multiple regulatory milestones (three NDAs) + strong cash runway into late 2028 meaningful for $773M company. Near-term FDA approvals highly material to business trajectory and commercial launch success.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.